Sex Transm Dis. 2018 Mar;45(3):177-182. doi: 10.1097/OLQ.0000000000000712.
The Centers for Disease Control and Prevention 2015 Sexually Transmitted Disease Treatment Guidelines recommend that clinicians consider cephalosporin treatment failure in patients who deny interval sexual exposure and are nucleic acid amplification test (NAAT) positive for Neisseria gonorrhoeae (NG) at least 7 days after adequate treatment. We evaluate the real-world implications of the interval the Centers for Disease Control and Prevention recommends for a NAAT test-of-cure (TOC), by ascertaining the frequency of NG NAAT positivity at different anatomic sites among men who have sex with men (MSM) at TOC 7 to 30 days after treatment.
We analyzed data from the medical records of MSM with laboratory-confirmed NG who were presumptively treated for NG during the period from June 2013 to April 2016 and returned for a TOC visit within 30 days. Data examined included symptoms, site of NG specimen collection, treatment regimen, follow-up testing, and intervening sexual activity.
There were 1027 NG-positive specimens obtained from 763 MSM patients at 889 presumptive treatment visits. Of these, 44% (337/763) MSM returned for 1 or more TOC visits, and 413 specimens were collected a median of 10 days after presumptive treatment. Three percent (14/413) of specimens collected were NG NAAT positive at TOC a median of 13 days after treatment: 5% (12/256) of urethral specimens, 1% (1/147) of anorectal specimens (P = 0.037, urethral vs. anorectal), and 10% (1/10) of oropharyngeal specimens (P = 0.40, urethral vs. oropharyngeal).
A small percent of patients were NG NAAT positive at TOC. Compared with anorectal specimens, urethral specimens were more frequently still positive at TOC. A large proportion of MSM will return for a TOC visit as part of standard clinical care.
疾病预防控制中心 2015 年性传播疾病治疗指南建议,对于否认间隔性性接触且淋病奈瑟菌核酸扩增试验(NAAT)至少在充分治疗后 7 天呈阳性的患者,临床医生应考虑头孢菌素治疗失败。我们通过确定治疗后 7 至 30 天接受性传播疾病检测的男性性接触者(MSM)中不同解剖部位的淋病奈瑟菌 NAAT 阳性率,评估了疾病预防控制中心建议的 NAAT 治愈检测(TOC)间隔时间的实际意义。
我们分析了 2013 年 6 月至 2016 年 4 月期间,实验室确诊为淋病奈瑟菌且接受推定淋病奈瑟菌治疗并在 30 天内进行 TOC 随访的 MSM 患者的病历数据。检查的数据包括症状、淋病奈瑟菌标本采集部位、治疗方案、随访检测和中间的性行为。
在 763 例 MSM 患者的 889 次推定治疗就诊中,获得了 1027 份淋病奈瑟菌阳性标本。其中,44%(337/763)的 MSM 进行了 1 次或多次 TOC 随访,413 份标本在推定治疗后中位数 10 天采集。在治疗后中位数 13 天的 TOC 中,3%(14/413)的标本淋病奈瑟菌 NAAT 阳性:5%(12/256)的尿道标本、1%(1/147)的肛门直肠标本(P=0.037,尿道比肛门直肠)和 10%(1/10)的口咽标本(P=0.40,尿道比口咽)。
一小部分患者在 TOC 时淋病奈瑟菌 NAAT 阳性。与肛门直肠标本相比,尿道标本在 TOC 时更常呈阳性。很大一部分 MSM 将作为标准临床护理的一部分返回进行 TOC 随访。